Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stellate Ganglion Block for Gastroesophageal Reflux Disease
NCT06319521Not yet recruiting
- Sponsor
- Copka Sonpashan
- Start
- Mar 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
01
Overview
Randomised, single-blind trial of lidocaine and vitamin b12 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Copka Sonpashan. Primary endpoint: Gastroesophageal Reflux Disease Questionnaire at Day 10. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
lidocainevitamin b12
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT06319521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319521.